Establishing validity of pharmacogenomic findings: From replication to triangulation

Circulation: Cardiovascular Genetics

Volumn 6, Issue 4, 2013, Pages 409-412

  Aslibekyan, Stella ^a   Claas, Steven A ^a   Arnett, Donna K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; REPLICATION STUDY; TRIANGULATION; CARDIOVASCULAR DISEASES; CLINICAL COMPETENCE; GENETICS; PHARMACOGENETICS; REPRODUCIBILITY; SINGLE NUCLEOTIDE POLYMORPHISM; REVIEW;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASES; CLINICAL COMPETENCE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS;

EID: 84884511762     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.112.000010     Document Type: Article

References (24)

1. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, et al. Replicating genotype-phenotype associations. Nature. 2007;447:655-660.
2. Sillanpää MJ, Auranen K. Replication in genetic studies of complex traits. Ann Hum Genet. 2004;68(Pt 6):646-657.
3. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet. 2001;29:306-309.
4. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet. 2010;11:241-246.
5. Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011;123:1661-1670.
6. Kraft P. Curses-winner's and otherwise-in genetic epidemiology. Epidemiology. 2008;19:649-651; discussion 657.
7. Siontis KC, Patsopoulos NA, Ioannidis JP. Replication of past candidate loci for common diseases and phenotypes in 100 genome-wide association studies. Eur J Hum Genet. 2010;18:832-837.
8. Ioannidis JP, Tarone R, McLaughlin JK. The false-positive to false-negative ratio in epidemiologic studies. Epidemiology. 2011;22: 450-456.
9. Peters BJ, Pett H, Klungel OH, Stricker BH, Psaty BM, Glazer NL, et al. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis. 2011;217:458-464.
10. N ordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, et al. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet Genomics. 2010;20:77-85.
11. Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet. 2009;2:173-181.
12. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N Engl J Med. 2008;359:789-799.
13. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005;5:352-358.
14. V oora D, Shah SH, Reed CR, Zhai J, Crosslin DR, Messer C, et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet. 2008;1: 100-106.
15. Greene CS, Penrod NM, Williams SM, Moore JH. Failure to replicate a genetic association may provide important clues about genetic architecture. PLoS One. 2009;4:e5639.
16. Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57-74.
17. Milan DJ, Kim AM, Winterfield JR, Jones IL, Pfeufer A, Sanna S, et al. Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation. 2009;120:553-559.
18. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008;118:355-362.
19. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet. 2006;38:209-213.
20. Kavvoura FK, Ioannidis JP. Methods for meta-Analysis in genetic association studies: a review of their potential and pitfalls. Hum Genet. 2008;123:1-14.
21. Lesnick TG, Sorenson EJ, Ahlskog JE, Henley JR, Shehadeh L, Papapetropoulos S, et al. Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway. PLoS One. 2008;3:e1449.
22. Li Y, Rowland C, Xiromerisiou G, Lagier RJ, Schrodi SJ, Dradiotis E, et al. Neither replication nor simulation supports a role for the axon guidance pathway in the genetics of Parkinson's disease. PLoS One. 2008;3:e2707.
23. Peng G, Luo L, Siu H, Zhu Y, Hu P, Hong S, et al. Gene and pathwaybased second-wave analysis of genome-wide association studies. Eur J Hum Genet. 2010;18:111-117.
24. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet. 2009;5:e1000337.